These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 27921038)

  • 21. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic landscape of autosomal dominant polycystic kidney disease in Kuwait.
    Ali H; Naim M; Senum SR; AlSahow A; Bahbahani Y; Abu-Farha M; Abubaker J; Mohammad A; Al-Hunayan A; Asbeutah AM; Zayed M; Devarajan S; Hussain N; John SE; Channanath A; Thanaraj TA; Al-Ali M; AlMousawi M; Al-Mulla F; Harris PC
    Clin Kidney J; 2023 Feb; 16(2):355-366. PubMed ID: 36755831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
    Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
    Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
    J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PKD1-Associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease.
    Shigemori K; Higashihara E; Itoh M; Yoshida H; Yamamoto K; Nutahara K; Shiokawa Y; Kaname S; Tambo M; Yamaguchi T; Taguchi S; Yoshioka T; Yokoyama K; Fukuhara H
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105943. PubMed ID: 34175641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetic analysis of polycystic kidney disease 1 and polycystic kidney disease 2 mutations in pedigrees with autosomal dominant polycystic kidney disease.
    Bitarafan F; Garshasbi M
    J Res Med Sci; 2019; 24():44. PubMed ID: 31160911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney Measurement and Glomerular Filtration Rate Evolution in Children with Polycystic Kidney Disease.
    Stroescu R; Gafencu M; Steflea RM; Chisavu F
    Children (Basel); 2024 May; 11(5):. PubMed ID: 38790570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
    Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
    PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autosomal dominant polycystic kidney disease: updated perspectives.
    Rastogi A; Ameen KM; Al-Baghdadi M; Shaffer K; Nobakht N; Kamgar M; Lerma EV
    Ther Clin Risk Manag; 2019; 15():1041-1052. PubMed ID: 31692482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational analysis in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Identification of five mutations in the PKD1 gene.
    Abdelwahed M; Hilbert P; Ahmed A; Mahfoudh H; Bouomrani S; Dey M; Hachicha J; Kamoun H; Keskes-Ammar L; Belguith N
    Gene; 2018 Sep; 671():28-35. PubMed ID: 29860066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
    Noël N; Rieu P
    Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying gene mutations of Chinese patients with polycystic kidney disease through targeted next-generation sequencing technology.
    Wang T; Li Q; Shang S; Geng G; Xie Y; Cai G; Chen X
    Mol Genet Genomic Med; 2019 Jun; 7(6):e720. PubMed ID: 31056860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
    Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological management of polycystic kidney disease.
    Wüthrich RP; Mei C
    Expert Opin Pharmacother; 2014 Jun; 15(8):1085-95. PubMed ID: 24673552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.
    Soroka S; Alam A; Bevilacqua M; Girard LP; Komenda P; Loertscher R; McFarlane P; Pandeya S; Tam P; Bichet DG
    Can J Kidney Health Dis; 2017; 4():2054358117695784. PubMed ID: 28321325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.